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tThe Ashkenazi Jewish population has a several-fold higher prevalence of Crohn’s disease
compared to non-Jewish European ancestry populations and has a unique genetic history.
Haplotype association is critical to Crohn’s disease etiology in this population, most notably at
NOD2, in which three causal, uncommon, and conditionally independent NOD2 variants reside on
a shared background haplotype. We present an analysis of extended haplotypes which showed
significantly greater association to Crohn’s disease in the Ashkenazi Jewish population compared
to a non-Jewish population (145 haplotypes and no haplotypes with P-value < 10−3, respectively).
Two haplotype regions, one each on chromosomes 16 and 21, conferred increased disease risk
within established Crohn’s disease loci. We performed exome sequencing of 55 Ashkenazi Jewish
individuals and follow-up genotyping focused on variants in these two regions. We observed
Ashkenazi Jewish-specific nominal association at R755C in TRPM2 on chromosome 21. Within
the chromosome 16 region, R642S of HEATR3 and rs9922362 of BRD7 showed genome-wide
significance. Expression studies of HEATR3 demonstrated a positive role in NOD2-mediated NF-
κ B signaling. The BRD7 signal showed conditional dependence with only the downstream rare
Crohn’s disease-causal variants in NOD2, but not with the background haplotype; this elaborates
NOD2 as a key illustration of synthetic association.
Keywords
haplotype association; Ashkenazi Jewish; Crohn’s disease; NF-κ B signaling; synthetic association
Introduction
Crohn’s disease (CD) is a complex genetic disorder characterized by chronic intestinal
inflammation resulting from a dysregulated host immune response to intestinal microbiota.1
The NOD2 gene, involved in innate immune responses to bacterial peptidoglycan, is
strongly associated with Crohn’s disease and was initially identified through genetic
linkage.2 Uncommon, loss-of-function coding mutations (Arg702Trp, Gly908Arg,
Leu1007fsinsC) in NOD2 confer a 17.1 fold (95% CI: 10.7 – 27.2) increased risk for disease
with homozygous or compound heterozygote risk allele carriage.3 The advent of genome-
wide association studies (GWAS) has resulted in the identification of 140 loci with genome-
wide significance in CD, implicating numerous immune mechanisms in disease
pathogenesis. However, most identified loci involve variants of modest effects, and the
presently identified 140 genetic loci account for only 13.6% of the estimated heritability.4
Because genotyping platforms utilized thus far have focused on common variants, it is
possible that untested rare mutations may contribute significantly to complex disorders and
account for some portion of missing heritability. Furthermore, precise models of disease
pathogenesis integrating multiple disease associations are largely lacking, reflecting in part
the significant pathophysiologic heterogeneity underlying the myriad associations reported
thus far in Crohn’s disease. Approaches to reduce genetic complexity, such as through
focused studies in selected populations, may be of benefit.
The Ashkenazi Jewish population has a several-fold higher prevalence of Crohn’s disease
compared to non-Jewish European ancestry cohorts, with estimates of increased prevalence
ranging between 4.3 to 7.7-fold.5,6 The Ashkenazim have a unique genetic history,
characterized by population bottlenecks, expansions and endogamy.7 However, the
associated polymorphisms identified thus far through genome-wide association studies, as
well as at NOD2, do not account for the higher disease prevalence in the Ashkenazim.
Although the basis for the increased frequency of CD in the Ashkenazim is not known, it is
possible that unidentified, uncommon variants, unique to or at a higher frequency within
Ashkenazi Jews, contribute to higher disease prevalence. An additional possibility, given the
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tgreater linkage disequilibrium observed within the Ashkenazim, is that multiple functional
polymorphisms inherited in cis, contribute to disease more commonly within Ashkenazi
Jewish compared to non-Jewish European ancestry populations. Such a configuration of
mutations would be consistent with the well-documented presence of longer haplotype
blocks with greater levels of linkage disequilibrium, relative to non-Jewish populations.8,9
As such, association testing to identify significant extended regions may point the way to
understanding the unique genetic architecture underlying Crohn’s disease in Ashkenazi
Jews.
Studying haplotype structure in the context of disease association also informs our
conception of synthetic association, which has been hypothesized to be a major contributor
to genome-wide association signals. Under this framework, molecular evolution, which
creates varying amounts of haplotype diversity, allows for significant disease association
near clusters of rare causal variants.10 For example, in CD, NOD2 is distinguished by three
uncommon functional mutations whose carriers are a subset of individuals who have a
common background haplotype.3,11 The multiple hierarchical levels in the tree-based
genealogy originally proposed by Dickson, et al., are reflected in various stringencies for the
clustering parameters in an analysis of contemporary haplotype diversity; for analyses with
strict parameters, causal variants may not lie within the associated haplotypes themselves.
Using haplotypes may be a particularly powerful approach for tagging functional variants; a
recent study found that using a multi-marker method for predicting Crohn’s disease risk
showed improved power over a single-variant approach.12 Toward this end, we present an
analysis using extended shared haplotypes as a filter for prioritizing novel variants and
detecting conditional dependence structure.
Results
Extended haplotype analysis
To address the presence and relevance to disease of extended linkage disequilibrium
stretches, we performed a haplotype-based analysis of a cohort comprising 397 Ashkenazi
Crohn’s disease cases and 431 controls, and 547 non-Ashkenazi Crohn’s disease cases and
549 controls.13,14 Our analysis of associated extended haplotypes showed that there were
markedly distinct patterns of haplotype association signals in the Ashkenazim compared to
the non-Jewish cohort (Figure 1). We observed 145 haplotypes demonstrating nominal
evidence for association with P-values < 10−3, including three distinct regions with P-values
< 10−4 (Supplementary Table 2). At this threshold, no regions were found to be significant
in the non-Jewish cohort. Comparing the 145 haplotypes with 71 previously identified
Crohn’s disease loci in a GWAS-based meta-analysis,15 we found that there were four
haplotypes overlapping three established loci (Table 1); no haplotypes overlapped the 69
additional CD-associated loci in a larger Immunochip-based study.4 Among all loci, the
most significant haplotype association signal was found at chromosome 16q12 in a region
that includes the NOD2 gene. Three of these four haplotypes showed higher allele
frequencies in Crohn’s disease cases, corresponding to increased disease risk, while the
remaining haplotype on chromosome 2 appeared to confer a protective function.
Chromosome 16 haplotypes—Two of the significant haplotypes in established CD loci
(chr16_hap6721 and chr16_hap6830) were located contiguously on chromosome 16,
spanning 48.88 – 49.18 and 49.18 – 49.48 Mb, respectively (Table 1). Haplotype
chr16_hap6830 was carried by 25 Crohn’s disease Ashkenazi cases and 4 Ashkenazi
controls, and chr16_hap6721 was carried by 15 Crohn’s disease cases and no controls. The
15 Crohn’s disease cases that carried chr16_hap6721 were completely a subset of the 25
cases that carried chr16_hap6721. Importantly, of these 15 Crohn’s disease extended
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thaplotype carriers, 12 also carried the Gly908Arg polymorphism within the NOD2 gene. Of
the three major disease-associated polymorphisms, only the Gly908Arg variant is present at
a significantly higher frequency in Ashkenazi compared to non-Ashkenazi Crohn’s disease
cases.16–22 NOD2 encodes an intracellular pathogen recognition receptor that functions as a
sensor for peptidoglycan found in the cell wall of most bacteria. In response to stimulation
by a component of bacterial peptidoglycan, muramyl dipeptide (MDP), NOD2 signaling
leads to the activation of the NF-κ B (nuclear factor of kappa light polypeptide gene
enhancer in B-cells) family of transcription factors.23,24 In addition to the established
association signal at NOD2, the associated region on chromosome 16 also contained the
BRD7 (bromodomain containing 7) gene, which has demonstrated genome-wide significant
association at rs9922362 (P-value = 3.26 × 10−16) in a GWAS dataset, separate from the one
used in the haplotype analysis, comprising 907 Ashkenazi CD and 2345 Ashkenazi controls
(Figure 2).25 BRD7 lies within 350Kb of NOD2 and encodes a protein involved in
chromatin remodeling.26 Notably, the GWAS dataset did not show any evidence for
independent association in CYLD (cylindromatosis), which is immediately adjacent to
NOD2, as has previously been reported.27
Chromosomes 2 and 21 haplotypes—Like the chromosome 16 region, the haplotype
on chromosome 21, chr21_hap8015 (chr21: 44.47 – 44.65 Mb) also spans multiple immune-
diseases related genes, such as ICOSLG (inducible T-cell co-stimulator ligand) and AIRE
(autoimmune regulator). The chromosome 2 haplotype, chr2_hap10940 (chr2: 61.18 – 61.87
Mb), which had a higher frequency in controls compared to cases, was within 125Kb of
COMMD1 (copper metabolism [Murr1] domain containing 1), a regulator of the NF-κ B
signaling pathway.
Exome sequencing
To further explore the haplotype regions of interest, we performed exome sequencing on 55
Ashkenazi Jewish samples, including 50 Crohn’s disease cases and 5 healthy controls. The
samples’ Jewish ancestry was validated genetically using GWAS data, and the case samples
included two carriers each of the risk haplotypes on chromosomes 16 and 21. Within the
associated haplotype regions chromosomes 16 and 21, we identified 40 previously
unreported missense or nonsense polymorphisms among all 55 Ashkenazi Jewish
individuals sequenced (Supplementary Table 3). None of the coding variants identified in
the chromosome 2 haplotype were predicted by Polyphen-2 to be probably damaging in
function, and no further investigation of these SNPs was conducted.28
Chromosome 21 haplotype—We identified a number of previously unreported
missense or nonsense uncommon mutations within the TRPM2 (transient receptor potential
cation channel, subfamily M, member 2) gene, including three polymorphisms, Arg755Cys,
Gln953Stop and Thr1347Met, predicted by PolyPhen-2 to be probably damaging in
function. Genotyping of these three SNPs was performed using Taqman assays on a follow-
up Ashkenazi cohort of 1220 cases and 1167 healthy controls (Supplementary Table 1).
Table 2 summarizes the association evidence for the three TRPM2 variants. We observed
nominal evidence for association (P-value = 0.0015) for the most common of these variants,
Arg755Cys in the Ashkenazi Jewish Crohn’s disease cohort. At this SNP, in a comparably-
sized non-Jewish cohort (915 non-Jewish European ancestry Crohn’s disease cases, and 818
matched healthy controls), we observed no evidence for association (P-value = 0.725). In
contrast to Arg755Cys, we observed no evidence for association in the Jewish cohort for
either Gln953stop or Thr1347Met in TRPM2. Of interest, the Gln953stop variant is carried
by an individual carrying the chromosome 21 risk haplotype (Table 1) and is specific to the
Ashkenazi Jewish population, not being observed in a subset of the non-Jewish European
ancestry samples comprising 192 Crohn’s disease cases and 192 healthy controls. Additional
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Ashkenazi Jewish Crohn’s disease.
Chromosome 16 haplotypes—Within the region encompassing the chromosome 16
risk haplotypes (Table 1), we identified 21 missense or nonsense mutations among the 55
individuals undergoing exome sequencing (Supplementary Table 3). While most of the
carriers of the chromosome 16 risk haplotypes also carry the NOD2 Gly908Arg variant, the
converse is not true; in the initial GWAS cohort, only 15 of the 68 Gly908Arg carriers
(22%) also carried the extended chromosome 16 risk haplotypes. We then asked whether
carriers of the extended risk haplotype might carry additional risk alleles. Importantly, two
extended chromosome 16 risk haplotype carriers also carried a previously unidentified
missense mutation, Arg642Ser, in HEATR3. The HEATR3 gene encodes a 680 amino acid
protein, and the Arg642Ser polymorphism is highly conserved between species and
predicted to be probably damaging to gene function by PolyPhen-2.
Fine mapping of chromosome 16 haplotypes
To more precisely define the nature of the various association signals in the NOD2
haplotype, we performed single-point and logistic regression analyses on the region’s key
markers in the 1167 Ashkenazi cases and 1220 Ashkenazi controls described above (Table
2). Consistent with prior reports, the Gly908Arg variant is the most common NOD2 risk
allele (10.4% minor allele frequency in cases) in the Ashkenazi Jewish cohort; this is in
contrast to non-Jewish European ancestry Crohn’s disease cohorts, where the frameshift
mutation, Leu1007fsinsC, is the most common.19,29 The Arg642Ser variant in HEATR3
(3.2% minor allele frequency in cases) is highly associated with Crohn’s disease (P-value =
3.53 × 10−7). We genotyped the Arg642Ser variant using Sanger sequencing in 384 non-
Jewish European ancestry Crohn’s disease cases and identified no carriers, indicating an
Ashkenazi Jewish predominance for this novel variant. Because the HEATR3 Arg642Ser
variant is present in Ashkenazi Jews on an extended risk haplotype also containing the more
common NOD2 Gly908Arg allele (D’ between Arg642Ser in HEATR3 and Gly908Arg in
NOD2 = 0.828), we next performed conditional logistic regression analysis to test for
additional conditionally dependent relationships. Several models were compared using the
Akaike Information Criterion (AIC) to determine the best subset of SNPs. Additive,
dominant and factor coding for the SNP genotypes were examined during the modeling
stage. The final model with minimum AIC contained the associated marker in BRD7,
rs9922362, as well as all four SNPs in NOD2, but not Arg642Ser in HEATR3. Under this
regression model, Gly908Arg in NOD2 demonstrated the most significant evidence for
association (P-value = 1.66 × 10−13). Additionally, in a full model containing all six variants
across the three genes, a conditional relationship to NOD2 accounted for much of the
association evidence observed at HEATR3 Arg642Ser variant (P-value = 0.333).
HEATR3 knockdown and over-expression
Although the genetic association signal at Arg642Ser in HEATR3 on chromosome 16 did
not appear to be independent, we noted that this gene is highly expressed in innate immune
cells,30 and we thus investigated its function in regulating NOD2 signaling. To test this, we
transiently knocked down HEATR3 using siRNA in cells stably expressing NOD2 and
stimulated them with muramyl dipeptide in order to activate NOD2 signaling. We monitored
NOD2-dependent signaling using both NF-κ B activation, as measured by a luciferase
reporter assay (Promega, Madison, WI), and IL-8 secretion, as measured by ELISA assay.
Cells transfected with siRNA targeting HEATR3 showed no significant loss in cell viability
but resulted in reduced MDP-induced NF-κ B activation and greater than 50% reduction in
IL-8 secretion compared to non-targeting siRNA controls. These results suggest that
HEATR3 is a positive regulator of NOD2 signaling. To further establish this relationship,
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twe also over-expressed HEATR3 in HEK293 cells stable expressing NOD2. Cells over-
expressing HEATR3 exhibited increased luciferase activity and increased IL-8 secretion,
thereby establishing a role for HEATR3 in positively regulating NOD2 signaling (Figure 3).
Discussion
The chromosome 16 associations at BRD7 and NOD2 represent an empirical paradigm of
synthetic association that illustrates and extends the proposals of Dickson, et al.10 Using
computer simulation, the researchers demonstrated that a cluster of low frequency, highly
penetrant mutations often occurs stochastically more frequently with one allele than the
other at a common SNP, resulting in “synthetic” association signals at these common
variants. While it has been argued that synthetic associations are not common in general, the
interactions between and within BRD7 and NOD2 provide an important illustration of the
complexities inherent in regression analyses to identify independent alleles. The minor allele
(minor allele frequency 25.5% in healthy controls) at the common NOD2 polymorphism
rs2076756 tags a shared haplotype on which four independent, causal, and uncommon
NOD2 variants (Arg702Trp, Asn852Ser, Gly908Arg, Leu1007fsinsC) completely reside.
This has been widely acknowledged as an example of synthetic association, as the NOD2
GWAS signal is created by this cluster of rare variants with high effect, and the signal is
mappable using linkage, which was originally predicted by Dickson et al.10,31
In our analysis, common variants at BRD7 (rs9922362) and NOD2 (rs2076756) appeared to
confer independent evidence for association, with P-values = 1.42 × 10−13 and 3.25 × 10−13,
respectively, in a logistic regression model consisting of the two SNPs. After conditioning
the BRD7 SNP on four uncommon causal NOD2 variants, however, the BRD7 association
signal largely diminishes (conditional P-value = 0.0292). Taken together, these statistical
results imply that the BRD7 SNP functions as a partial background for the directly causal
NOD2 mutations, but not for the entire NOD2 IBD-associated haplotype. This is visualized
more directly in Figure 4, which shows that the BRD7 SNP indeed does not appear to
simply be associated through linkage disequilibrium with the NOD2 background SNP, but
rather that its carriers are enriched for the rare causal variants within the NOD2 background
haplotype. Importantly, the 0.4 Mb distance between the BRD7 variant and NOD2 is
consistent with the findings by Dickson, et al. which showed that causal relationships can
extend over long regions surrounding synthetic association, in the range of several
megabases. However, we note that the absence of conditional dependence between the two
common background SNPs in BRD7 and NOD2 conflicts with the hierarchical genealogy
model supported by Dickson, et al. Overall, the example of Crohn’s disease illustrates the
variability of conditioning on highly associated, non-causal background variants such as the
NOD2 common haplotype background variant, rs2076756, as opposed to functional
uncommon variants.
In this study, we report associations of uncommon extended haplotypes in Ashkenazi
Jewish, but not non-Jewish European ancestry populations, thereby illustrating the greater
power of this approach in endogamous populations. The haplotype associations on
chromosome 16 tag the Gly908Arg variant within NOD2, the most prevalent causal
mutation in Ashkenazi Jewish populations. The extended haplotype carriers in this region
tag a less common, Ashkenazi Jewish-specific variant, Arg642Ser in HEATR3, which we
demonstrated to function in the NOD2 pathway. Given the extensive linkage disequilibrium
between Gly908Arg in NOD2 and Arg642Ser in HEATR3, however, we did not observe
independent evidence for association for the HEATR3 SNP. This marker, along with others
in TRPM2 on chromosome 21, demonstrated the capability of our haplotype-based analysis
to direct the discovery of new disease-associated and population-specific polymorphisms.
Furthermore, the extended length of the Jewish-specific haplotypes may indicate the
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tpresence of long-distance conditional relationships, as in the case of rs9922362 of BRD7
and the NOD2 causal variants on chromosome 16, an example of synthetic association. As
additional fine-mapping studies of GWAS loci are reported, an increasing number of
population-specific polymorphisms and haplotypes will be identified. The etiology for the
higher prevalence of Crohn’s disease in the Ashkenazi Jewish population remains largely
undefined; however, our study indicates that extended haplotypes containing multiple
functional polymorphisms inherited in cis may contribute in a population-specific manner.
Materials and Methods
Subjects
Three hundred and ninety-seven Ashkenazi Crohn’s disease cases and 431 controls, and 547
non-Ashkenazi Crohn’s disease cases and 549 controls (Supplementary Table 1) were
ascertained through Genetics Research Centers in Baltimore, Chicago, Montreal, Pittsburgh,
Los Angeles, and Toronto, and through the New York Health Project. In all cases, informed
consent was obtained following protocols approved by each local institutional review board.
Diagnostic inclusion and exclusion criteria are described elsewhere.13 Ashkenazi Jewish
ancestry was validated using principal components analysis.
Genotyping and haplotype association analysis
Genomic DNA was isolated from whole blood from the case-control cohort. Genotyping
was performed on the Illumina HumanHap300 platform, with an average inter-marker
distance less than 10Kb. All samples had genotype yields greater than 94%, and missing
genotypes were imputed using BEAGLE 3.1.0 with default parameters.32 Analysis was
performed using GERMLINE 1.5.0 (Genetic Error-tolerant Regional Matching with LINear-
time Extension), a computationally efficient program for identifying shared identical-by-
descent segments between pairs of individuals in a large population, and DASH 1.1.0
(DASH Associates Shared Haplotypes), a program for clustering these segments into
haplotype regions that are shared by multiple individuals.33,34 Our analysis utilized default
parameters, with a minimum haplotype length of 3 Mb and a maximum of 4 homozygous
mismatches between shared segments. In the Ashkenazi samples, 473,621 haplotype clusters
across the autosomes were tested for association, compared to 8,986 clusters in the non-
Jewish samples. Due to correlation between the haplotype clusters, precise multiple testing
corrections could not be calculated, but given that all clusters in the Jewish and non-Jewish
analyses had P-values greater than 10−5 and 10−3, respectively, it was clear that none were
genome-wide significant.
Exome sequencing and variant screening
Genomic DNA was extracted from whole blood and whole-exome captured with the
NimbleGen 2.1 M human exome array following the manufacturer’s protocol (Roche/
NimbleGen, Madison, WI). Captured libraries were sequenced on the Illumina genome
analyzer as paired-end 75-bp reads, following the manufacturer’s protocol. Sequence reads
were mapped to the reference genome (hg18) using the BWA program using default
parameters.35 The Genome Analysis Toolkit (GATK) v2 was used to call alleles at variant
sites.36 Sample-level realignment and multi-sample SNP calling were performed using
default parameters and the GATKStandard variant filter.
HEATR3 knockdown and over-expression
HEK293 cells stably expressing NOD2 were cultured in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, and 1x
penicillin-streptomycin (Gibco, Grand Island, NY). All experiments were performed in
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tduplicate. In the silencing experiments, these cells were then reverse-transfected with
siGENOME siRNA pools (Thermo Scientific, Hudson, NH) targeting HEATR3 (or non-
targeting siRNA as a negative control) at a concentration of 20 nM with the lipid
transfection agent Lipofectamine 2000 (Invitrogen, Grand Island, NY) diluted in Opti-MEM
(Invitrogen) for 48 hours. Cells were either left unstimulated or subsequently stimulated
with MDP (20 ng/ml; Bachem, Torrance, CA) for 18 hours. In the over-expression
experiment, HEK293 cells were transiently transfected using Lipofectamine 2000 with a
pCMV-SPORT6 based expression plasmid encoding murine HEATR3 (Thermo Scientific),
followed by MDP stimulation as described above. Transfection with the empty vector was
used as a negative control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1.
Manhattan plot of haplotype associations in non-Ashkenazi Jewish (A) and Ashkenazi
Jewish (B) European Ancestry cohorts. In the non-Jewish analysis, no regions demonstrated
evidence for association. In contrast, in the Ashkenazim, we observed 145 haplotypes
demonstrating nominal evidence for association with P-values < 10−3, including three
distinct regions with P-values < 10−4. Associated haplotypes that overlapped with
established CD loci, and which are detailed in Table 1, are labeled.
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Single-marker associations in the chromosome 16 haplotype region. We observed genome-
wide significant associations at rs2076756 (P-value = 2.32 × 10−20) in NOD2 and rs9922362
(P-value = 3.26 × 10−16) in BRD7. Positions of two nominally associated Ashkenazi Jewish
haplotypes are shown by black bars at top.
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HEATR3 is a positive component of the NOD2 signaling pathway. siRNA mediated knock
down of HEATR3 diminished NOD2-dependent NF-κ B induction (A) and IL-8 secretion
(B) relative to non-targeting siRNA controls. Furthermore, over-expression of HEATR3
increased NF-κ B signaling (C) and IL-8 production (D). Cells were left unstimulated (black
bars) or stimulated overnight with 20 ng/mL of MDP (grey bars). Together these results
support a positive role for HEATR3 in NOD2 signaling. * P<0.05, ** P<0.01, *** P<0.001.
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tFigure 4.
Venn diagram of carriers for chromosome 16 haplotype variants among healthy controls.
Numbers indicate the percentage of haploid chromosomes (n = 2440) that carry each
combination of mutations. Colors indicate causal mutations within NOD2: peach = R702W;
green = N852S; pink = G908R; blue = L1007insC. Missing genotypes and phasing of
haploid carriers were inferred using BEAGLE with default parameters. Regions representing
less than 0.5% of haploid carriers are not shown. These results indicate that both the
common BRD7 and NOD2 SNPs serve as backgrounds for the NOD2 uncommon causal
variants, which in turn serve as the basis for association at the these two common
background variants.
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